Search clinical trials for: Placebo of tolvaptan

Total 182105 results

Regional Hospital Holstebro
Aarhus University Hospital

Completed

Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA) (DOVA)

Nephropathy

Denmark
Otsuka Pharmaceutical Development & Commercialization...

Completed

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NOCTURNE)

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients

Heart Failure

Japan
University of North Carolina, Chapel Hill
Otsuka America Pharmaceutical

Completed

Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders (TROUPER)

Congestive Heart Failure

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Chronic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease

Australia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney (ARPKD)

United States, United Kingdom, Belgium, Poland, France, Germany, Italy
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Cardiac Edema

Japan
NYU Langone Health

Withdrawn

Fractional Urate Excretion in Nonedematous Hyponatremia

SIADH | Cerebral Hyponatremia | Cerebral Salt-wasting Syndrome | Reset Hypothalamic Osmostat

United States
Cardiovascular Clinical Science Foundation

Completed

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management (Secret of CHF)

Heart Failure

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Germany, Italy, Belgium, United Kingdom
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male

Healthy

Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Completed

Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

Polycystic Kidney, Autosomal Dominant

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Japan
University of North Carolina, Chapel Hill
Otsuka America Pharmaceutical

Completed

Pilot Study of Using Copeptin to Predict Response to Tolvaptan

Heart Diseases | Cardiovascular Diseases | Heart Failure

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Inappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte Imbalances

United States
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH

Antidiuretic Hormone, Inappropriate Secretion

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Edema, Cardiac

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Germany, United Kingdom, Spain, Sweden, Hungary, Czech Republic, Denmark
Otsuka Beijing Research Institute

Completed

Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis

Ascites | Hepatic Cirrhosis

China
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH

Syndrome of Inappropriate Antidiuretic Hormone Secretion

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)

Cardiac Edema

Japan
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
University of Chicago

Completed

Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients (TOLVAD)

Heart Failure | Heart Assist Device | Hyponatremic

United States
Brigham and Women's Hospital
Otsuka Pharmaceutical Co., Ltd.

Completed

The Role of Vasopressin Antagonism on Renal Sodium Handling

Healthy
Otsuka Pharmaceutical Development & Commercialization...

Completed

Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure

Heart Failure, Congestive

United States, Romania
Gia Dinh People Hospital
Otsuka Pharmaceutical Vietnam

Recruiting

Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF)

Acute Heart Failure

Vietnam
Assistance Publique - Hôpitaux de Paris
Otsuka Pharmaceutical Europe Ltd

Unknown

Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) (TOLVATHIRST)

Healthy Volunteers

France
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)

Edema | Heart Failure, Congestive

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

Congestive Heart Failure

Japan
Shanghai Chest Hospital

Completed

The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

Right Heart Failure | Tricuspid Regurgitation

China
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia (SALACIA)

Hyponatremia | Inappropriate ADH Syndrome | Dilutional Hyponatremia

United States
Otsuka Beijing Research Institute
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Hypovolemic Hyponatremia

China
Eli Lilly and Company

Active, not recruiting

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Plaque Psoriasis | Psoriatic Arthritis

India
Taiwan Otsuka Pharm. Co., Ltd

Completed

Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure

Cardiac-induced Edema

Taiwan
Maisel, Alan, M.D.
Otsuka Pharmaceutical Development & Commercialization, Inc.; Thermo Fisher...

Unknown

Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE) (ACTIVATE)

Acute Heart Failure
Regional Hospital Holstebro

Completed

Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD (POLY)

Polycystic Kidney, Autosomal Dominant

Denmark
Duke University

Completed

Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure (TACTICS-HF)

Heart Failure | Dyspnea

United States
Otsuka Beijing Research Institute

Completed

Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema

Cardiac Edema

China
Otsuka Beijing Research Institute

Completed

Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites

Ascites | Hepatic Cirrhosis

China
Korea Otsuka Pharmaceutical Co., Ltd.

Terminated

Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites (ECF)

Hyponatremia and Extracellular Fluid in Cirrhotic

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Withdrawn

A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia

Hyponatremia
University of Michigan
Otsuka Pharmaceuticals

Withdrawn

The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study

Heart Failure

United States
Jiangsu HengRui Medicine Co., Ltd.
Beijing Friendship Hospital; Beijing 302 Hospital; Beijing Anzhen Hospital

Unknown

Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Non-hypovolemic Non-acute Hyponatremia

China
Korea Otsuka Pharmaceutical Co., Ltd.

Terminated

Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure (AQUATIC)

Heart Failure With Hyponatremia

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients (INSIGHT)

Hyponatremia

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema

Cirrhosis

Japan
Otsuka Beijing Research Institute

Completed

Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

Ascites | Hepatic Cirrhosis

China
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Tolvaptan in Hyponatremic Cancer Patients

Advanced Cancers

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Polycystic Kidney Disease, Autosomal Dominant

United States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany

Search clinical trials for: Placebo of tolvaptan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations